Abstract 78P
Background
Breakpoint cluster region-Abelson (BCR:ABL1) gene fusion is an essential oncogene in both chronic myeloid leukemia (CML) and Philadelphia-positive (Ph+) B-cell acute lymphoblastic leukemia (B-ALL). While tyrosine kinase inhibitors (TKIs) are effective in up to 95% of CML patients, 50% of Ph+ B-ALL cases do not respond to treatment or relapse. This calls for new therapeutic approaches for Ph+ B-ALL. Dysregulation of redox homeostasis and reliance on the thioredoxin (TXN) antioxidant system has been previously shown in B-ALL. Herein, we investigated the role of peroxiredoxin-1 (PRDX1), an enzyme responsible for the scavenging of hydrogen peroxide, in Ph+ myeloid and lymphoid leukemia.
Methods
PRDX1 knockout and apoptotic proteins were assessed by immunoblotting. The numbers of viable BV173 (lymphoid) and K562 (myeloid) cells were evaluated by light microscope counting after discriminating dead cells with Trypan Blue staining. Cell cycle and proliferation were assessed with MUSE and Click-iT EdU tests, respectively. The viability of K562 and BV173 knockouts treated with TKIs was assessed with propidium iodide staining and flow cytometry.
Results
PRDX1 knockout reduced the numbers of viable BV173 cells grown in vitro, but did not affect the numbers of K562 cells. The addition of hydrogen peroxide scavenges to the culture medium restored the viability of BV173 cells. We observed no significant differences in cell proliferation or in cell cycle fractions in BV173sgPRDX1 cells. Notably, in contrast to the myeloid K562 cell line, lymphoid B-ALL cells lacking PRDX1 were much more sensitive to three tested TKIs: imatinib, dasatinib, and ponatinib.
Conclusions
The results reveal that the important role of PRDX1 for Ph+ leukemic cell viability and sensitivity to TKIs is restricted to lymphoid leukemias. The observed reduced numbers of PRDX1 knockout cells were not the effect of an altered cell cycle or proliferation but most likely due to increased apoptosis. These findings are part of a larger ongoing in vitro and in vivo study examining the sensitization of Ph+ lymphoid leukemia to TKIs through inhibition of the thioredoxin system and PRDX1.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical University of Warsaw.
Funding
SONATA BIS 2015/18/E/NZ5/00723 grant funded by the National Science Centre, entitled “Novel pro-oxidative strategies in the treatment of B cell acute lymphoblastic leukemia”.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4P - Spatially resolved transcriptome elucidates bidirectional tertiary lymphoid structure interacts with tumor microenvironment of non-small cell lung cancer
Presenter: Xin Zhao
Session: Poster session 09
5P - Tertiary lymphoid structures (TLS) presence and stromal blood vessels heterogeneity differentially influence recurrence, lymphovascular, and perineural invasion in breast cancer molecular subtypes
Presenter: Andrei Cosma
Session: Poster session 09
6P - Combined single-cell and spatially resolved mapping of the human lymph node ecosystem reveals fundamental principles of lymphoma tissue organization
Presenter: Daniel Hübschmann
Session: Poster session 09
7P - Engineered salmonella blocks cancer metastasis by activating NK cells in an IFN-γ-dependent manner
Presenter: JIANDONG HUANG
Session: Poster session 09
8P - Modulating tumor microenvironment using a VEGF active immunotherapeutic approach in gastrointestinal tumors: Beyond angiogenesis modulation
Presenter: Mónica Bequet-Romero
Session: Poster session 09
9P - Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model
Presenter: Giulia Mazzaschi
Session: Poster session 09
10P - Cancer cells induce intracellular gap formation in sinusoidal endothelial cells to produce liver metastasis through pro-inflammatory paracrine mechanisms
Presenter: Hoang Truong
Session: Poster session 09
11P - Targeting stromal cells to reverse immune suppression in triple-negative breast cancer
Presenter: Julia Chen
Session: Poster session 09
12P - Immuno-suppressive role of tumour-derived GDF-15 on myeloid cells
Presenter: Christine Schuberth-Wagner
Session: Poster session 09
13P - Disrupting the immunosuppressive tumor microenvironment using genetically engineered macrophages for triple-negative breast cancer therapy
Presenter: Sabrina Traxel
Session: Poster session 09